|
Brain Neoplasms
|
0.500 |
CausalMutation
|
group |
CGI |
|
|
|
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
20160062 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias.
|
22343896 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH mutation screening is rapidly becoming part of the routine pathological work up of human brain tumors, providing both diagnostic and prognostic information.
|
23307057 |
2013 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Acquired somatic mutations of IDH1 and IDH2 have recently been reported in some types of brain tumors and a small proportion of acute myeloid leukemia (AML) cases.
|
22397365 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
|
23558169 |
2013 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Another mitochondrial and TCA cycle-related protein, isocitrate dehydrogenase 2 is, together with IDH1, frequently mutated in the brain tumour glioblastoma.
|
20304625 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Arch Pathol Lab Med 138:241-256, 2014) in addition to serving as surrogate markers for molecular alterations in neoplasms, including IDH1 and ATRX mutations in brain tumors (Appin CL, Brat DJ.Mol Aspects Med.45:87-96, 2015).
|
30539453 |
2019 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
|
19903171 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.
|
22427879 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Cytosolic isocitrate dehydrogenase 1 (IDH1) with an R132H mutation in brain tumors loses its enzymatic activity for catalyzing isocitrate to α-ketoglutarate (α-KG) and acquires new activity whereby it converts α-KG to 2-hydroxyglutarate.
|
24077277 |
2013 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Exon 4 of IDH1 and IDH2 was analyzed in a series of brain tumors classified according to current WHO criteria.
|
29535392 |
2018 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Genetic alterations of IDH1 and Vegf in brain tumors.
|
28948065 |
2017 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors.
|
22015945 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here, we describe the isolation of a glioma brain tumor stem cell line (BT142) with an endogenous R132H mutation in IDH1, aggressive tumor-initiating capacity, and 2-HG production.
|
22166263 |
2012 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown.
|
19359588 |
2009 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we address this need by presenting a proton magnetic resonance spectroscopy ((1)H-MRS) acquisition scheme that uses an ultrahigh magnetic field (≥ 7T) capable of noninvasively detecting 2-HG with quantitative measurements sufficient to differentiate mutant cytosolic IDH1 and mitochondrial IDH2 in human brain tumors.
|
26669865 |
2016 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Increased overall survival for patients with glioma brain tumours is associated with mutations in the metabolic regulator isocitrate dehydrogenase 1 (IDH1).
|
27820599 |
2016 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Isocitrate Dehydrogenase-1 (<i>IDH1)</i> is a driver gene in several cancers including brain tumors such as low-grade and high-grade gliomas.
|
29971034 |
2018 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide.
|
28571041 |
2017 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Metrics used for this range from quantification of single oncometabolites (such as 2-hydroxyglutarate in mutant IDH1 glial brain tumours) to selected metabolite ratios (such as total choline to N-acetylaspartate (plain ratio or CNI index)) or the whole <sup>1</sup> H MRSI(I) pattern through pattern recognition analysis.
|
30633389 |
2019 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.
|
28148827 |
2017 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
|
21069360 |
2011 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been identified in a number of cancer types, including brain cancer.
|
29849122 |
2018 |